

Antonio Viãºdez

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/1825895/publications.pdf>

Version: 2024-02-01

45
papers

1,088
citations

471509

17
h-index

414414

32
g-index

47
all docs

47
docs citations

47
times ranked

2009
citing authors

#	ARTICLE	IF	CITATIONS
1	Liver disease induced by radioembolization of liver tumors. <i>Cancer</i> , 2008, 112, 1538-1546.	4.1	330
2	Lauren subtypes of advanced gastric cancer influence survival and response to chemotherapy: real-world data from the AGAMENON National Cancer Registry. <i>British Journal of Cancer</i> , 2017, 117, 775-782.	6.4	77
3	Safety and clinical activity of vascular endothelial growth factor receptor (VEGFR) tyrosine kinase inhibitors after programmed cell death 1 inhibitor treatment in patients with metastatic clear cell renal cell carcinoma. <i>Annals of Oncology</i> , 2016, 27, 1304-1311.	1.2	66
4	Oxaliplatin, irinotecan and capecitabine as first-line therapy in metastatic colorectal cancer (mCRC): a dose-finding study and pharmacogenomic analysis. <i>British Journal of Cancer</i> , 2010, 102, 987-994.	6.4	49
5	Nomogram-based prediction of survival in patients with advanced oesophagogastric adenocarcinoma receiving first-line chemotherapy: a multicenter prospective study in the era of trastuzumab. <i>British Journal of Cancer</i> , 2017, 116, 1526-1535.	6.4	46
6	Surgery for metastases for esophageal-gastric cancer in the real world: Data from the AGAMENON national registry. <i>European Journal of Surgical Oncology</i> , 2018, 44, 1191-1198.	1.0	42
7	1157O A multi-cohort phase II study of durvalumab plus tremelimumab for the treatment of patients (pts) with advanced neuroendocrine neoplasms (NENs) of gastroenteropancreatic or lung origin: The DUNE trial (GETNE 1601). <i>Annals of Oncology</i> , 2020, 31, S770-S771.	1.2	38
8	Nab-paclitaxel: A flattering facelift. <i>Critical Reviews in Oncology/Hematology</i> , 2014, 92, 166-180.	4.4	35
9	Epidermal growth factor receptor inhibitors in colorectal cancer treatment: What's new?. <i>World Journal of Gastroenterology</i> , 2007, 13, 5877.	3.3	35
10	Circulating Tumor Cells in Patients Undergoing Resection of Colorectal Cancer Liver Metastases. Clinical Utility for Long-Term Outcome: A Prospective Trial. <i>Annals of Surgical Oncology</i> , 2019, 26, 2805-2811.	1.5	27
11	Combining chemotherapy and targeted therapies in metastatic colorectal cancer. <i>World Journal of Gastroenterology</i> , 2007, 13, 5867.	3.3	26
12	Improving disease control in advanced colorectal cancer: Panitumumab and cetuximab. <i>Critical Reviews in Oncology/Hematology</i> , 2010, 74, 193-202.	4.4	24
13	SEOM clinical guideline thyroid cancer (2019). <i>Clinical and Translational Oncology</i> , 2020, 22, 223-235.	2.4	23
14	Pancreatic neuroendocrine tumors: Challenges in an underestimated disease. <i>Critical Reviews in Oncology/Hematology</i> , 2016, 101, 193-206.	4.4	21
15	Prognostic significance of performing universal HER2 testing in cases of advanced gastric cancer. <i>Gastric Cancer</i> , 2017, 20, 465-474.	5.3	20
16	The cancer outpatient satisfaction with care questionnaire for chemotherapy, OUT-PATSAT35 CT: a validation study for Spanish patients. <i>Supportive Care in Cancer</i> , 2012, 20, 3269-3278.	2.2	19
17	A new immunohistochemistry prognostic score (IPS) for recurrence and survival in resected pancreatic neuroendocrine tumors (PanNET). <i>Oncotarget</i> , 2016, 7, 24950-24961.	1.8	19
18	Retrospective analysis of pathological response in colorectal cancer liver metastases following treatment with bevacizumab. <i>Clinical and Translational Oncology</i> , 2014, 16, 739-745.	2.4	18

#	ARTICLE	IF	CITATIONS
19	Evaluating radiological response in pancreatic neuroendocrine tumours treated with sunitinib: comparison of Choi versus RECIST criteria (CRIPNET_ GETNE1504 study). <i>British Journal of Cancer</i> , 2019, 121, 537-544.	6.4	18
20	SEOM clinical guidelines for the diagnosis and treatment of gastroenteropancreatic and bronchial neuroendocrine neoplasms (NENs) (2018). <i>Clinical and Translational Oncology</i> , 2019, 21, 55-63.	2.4	17
21	Anthracycline-based triplets do not improve the efficacy of platinum-fluoropyrimidine doublets in first-line treatment of advanced gastric cancer: real-world data from the AGAMEMON National Cancer Registry. <i>Gastric Cancer</i> , 2018, 21, 96-105.	5.3	16
22	Quality of life assessment by applying EORTC questionnaires to rectal cancer patients after surgery and neoadjuvant and adjuvant treatment. <i>Revista Espanola De Enfermedades Digestivas</i> , 2013, 105, 255-261.	0.3	14
23	Efficacy and safety of chemotherapy in older versus non-older patients with advanced gastric cancer: A real-world data, non-inferiority analysis. <i>Journal of Geriatric Oncology</i> , 2018, 9, 254-264.	1.0	14
24	Phase I and Pharmacokinetic Study of Gemcitabine Administered at Fixed-Dose Rate, Combined with Docetaxel/Melphalan/Carboplatin, with Autologous Hematopoietic Progenitor-Cell Support, in Patients with Advanced Refractory Tumors. <i>Biology of Blood and Marrow Transplantation</i> , 2007, 13, 1324-1337.	2.0	12
25	Prognostic significance of thymidylate synthase polymorphisms in rectal cancer patients treated with neoadjuvant chemoradiotherapy. <i>Colorectal Disease</i> , 2013, 15, 428-435.	1.4	11
26	Fecal incontinence and radiation dose on anal sphincter in patients with locally advanced rectal cancer (LARC) treated with preoperative chemoradiotherapy: a retrospective, single-institutional study. <i>Clinical and Translational Oncology</i> , 2017, 19, 969-975.	2.4	11
27	Stereotactic body radiation therapy for liver metastasis from colorectal cancer: size matters. <i>Clinical and Translational Oncology</i> , 2020, 22, 2350-2356.	2.4	9
28	Local recurrence after five years is associated with preoperative chemoradiotherapy treatment in patients diagnosed with stage II and III rectal cancer. <i>International Journal of Surgery</i> , 2017, 44, 15-20.	2.7	8
29	Omics Approaches in Pancreatic Adenocarcinoma. <i>Cancers</i> , 2019, 11, 1052.	3.7	8
30	Optimal duration of first-line chemotherapy for advanced gastric cancer: data from the AGAMENON registry. <i>Clinical and Translational Oncology</i> , 2020, 22, 734-750.	2.4	8
31	Quality of life in elderly breast cancer patients with localized disease receiving endocrine treatment: a prospective study. <i>Clinical and Translational Oncology</i> , 2019, 21, 1231-1239.	2.4	8
32	Impact of initial FDG PET/CT in the management plan of patients with locally advanced head and neck cancer. <i>Clinical and Translational Oncology</i> , 2015, 17, 139-144.	2.4	5
33	Stellate cells, a point of light in the dark night of pancreatic cancer. <i>British Journal of Cancer</i> , 2014, 111, 1676-1677.	6.4	4
34	Clinical complete response in locally advanced rectal cancer: can we offer a wait-and-see policy?. <i>Annals of Oncology</i> , 2013, 24, 853.	1.2	2
35	Final results of a phase II single-institutional trial with hyperfractionated radiation therapy (HFX) and four-weekly continuous cisplatin in locally advanced head and neck carcinoma. <i>Clinical and Translational Oncology</i> , 2014, 16, 555-560.	2.4	2
36	Usefulness of an immunohistochemical score in advanced pancreatic neuroendocrine tumors treated with CAPTEM or everolimus. <i>Pancreatology</i> , 2021, 21, 215-223.	1.1	2

#	ARTICLE	IF	CITATIONS
37	1107P Durvalumab plus tremelimumab in patients with grade 3 neuroendocrine neoplasms of gastroenteropancreatic origin: Updated results from the multicenter phase II DUNE trial (GETNE 1601). <i>Annals of Oncology</i> , 2021, 32, S914-S915.	1.2	2
38	Unresectable Liver Metastases from Colorectal Cancer and Hepatic Arterial Infusion Chemotherapy: How, When and to Whom?. <i>CardioVascular and Interventional Radiology</i> , 2009, 32, 603-604.	2.0	0
39	Guidelines for diagnosis, staging and treatment of metastatic colorectal cancer by Grupo Español Multidisciplinar en Cancer Digestivo (GEMCAD). <i>Colorectal Cancer</i> , 2015, 4, 97-112.	0.8	0
40	Clinical guide SEOM: hepatocellular carcinoma (HCC): considerations on SBRT. <i>Clinical and Translational Oncology</i> , 2016, 18, 955-956.	2.4	0
41	Anthracycline-based triplets do not improve the efficacy of platinum-fluoropyrimidine doublets in advanced gastric cancer: AGAMENON study data. <i>Annals of Oncology</i> , 2017, 28, v224.	1.2	0
42	1167P SILVELLUL SCORE: An original or modified immunohistochemical score (IPS or mIPS) in patients (pts) with pancreatic neuroendocrine tumours (PanNET) treated with everolimus or CAPTEM. <i>Annals of Oncology</i> , 2020, 31, S775.	1.2	0
43	P-252 Serial cytokines as potential predictive/prognosis biomarkers in potentially resectable pancreatic adenocarcinoma. <i>Annals of Oncology</i> , 2020, 31, S172.	1.2	0
44	1099MO Durvalumab plus tremelimumab influence on response to subsequent treatments in patients with neuroendocrine neoplasms (NENs) of gastroenteropancreatic and lung origins: Results from the phase II DUNE trial (GETNE 1601). <i>Annals of Oncology</i> , 2021, 32, S909-S910.	1.2	0
45	Spinal meningioma diagnosis based on transesophageal endoscopic ultrasound-guided fine-needle aspiration (EUS-FNA). <i>Revista Espanola De Enfermedades Digestivas</i> , 2013, 105, 500-501.	0.3	0